The expression level of PLS3 did neither affect the amount of SMN nor did the other putative biomarkers, supporting the hypothesis that PLS3 acts as an independent protective modifier in SMA [196]. The gene discussed is PLS3; the disease is proximal spinal muscular atrophy.